Focusing in on the Regulatory Landscape for Allogeneic Cell Therapies

Time: 3:30 pm
day: Day Two


  • Examining acceptance criteria expectations around gene editing, toxicity, and potency assays
  • Highlighting importance of early CMC work to enable efficient manufacturing scale-up for allogeneic products
  • Evaluating opportunities to align global regulatory perspectives on allogeneic therapies